GlassScriptPhysician profile
Conrad Jablonski
NPI 1881899011
$48,443.48
in general payments reported to CMS, 2019-2025
17 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,257 · 2020: $3,327 · 2021: $6,879 · 2022: $22K · 2023: $4,698 · 2024: $9,030 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,512 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,300 · Food and Beverage: $1,969 · Consulting Fee: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,512.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,300.00 |
| Food and Beverage | $1,969.29 |
| Consulting Fee | $212.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $32,603.73 | 2021-2024 | Resolute Onyx, Symplicity G3, Micra |
| Shockwave Medical, INC | $4,043.07 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $3,860.16 | 2019-2020 | |
| Biotronik INC. | $3,439.78 | 2021-2022 | |
| Abbott Laboratories | $1,654.00 | 2019-2023 | Xience Skypoint, Optis |
| Philips North America LLC | $1,366.29 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Heartflow, INC. | $476.67 | 2023 | Ffrct |
| Novartis Pharmaceuticals Corporation | $263.47 | 2023-2025 | |
| Amgen INC. | $228.00 | 2021-2023 | Repatha |
| Pfizer INC. | $170.11 | 2023-2025 | |
| Boston Scientific Corporation | $166.74 | 2019-2025 | General - Vascular Intervention |
| Esperion Therapeutics, INC. | $48.29 | 2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $41.17 | 2025 | Camzyos |
| Cleerly, INC. | $33.81 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Novo Nordisk INC | $16.98 | 2025 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $15.87 | 2021 | |
| Glaxosmithkline, LLC. | $15.34 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Jablonski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.